Share on

North America Vaccine Contract Manufacturing Market Research Report – Segmented By Service Type, Product Type, Vaccine Type and Region - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2023 to 2028)

Published: March, 2023
ID: 7577
Pages: 145
Formats: report pdf report excel report power bi report ppt

North America Vaccine Contract Manufacturing Market Size (2023 to 2028)

The size of the Vaccine contract manufacturing market in North America is estimated to be valued at USD 417.17 million in 2023. It is expected to rise at a CAGR of 8.1% from 2023 to 2028 and be worth USD 615.81 million by 2028, largely because of technological advancements and good FDA initiatives.

Vaccine production is a complicated procedure in which the producers' primary concerns are efficacy, safety, and uniformity. Lower business time, infrastructure cost savings, and operational benefits are significant factors driving the growth of the North American vaccine contract manufacturing market. Furthermore, technological advances, such as the introduction of novel expression systems such as GPEx and EB66 cell lines and cell culture medium platforms, are likely to drive market expansion. Clients profit from vaccine contract services, and they save money. They also aid in the administration and operation of a production and research facility. These benefits of Contract Manufacturing Organizations (CMOs) are projected to help emerging players, start-ups, and small businesses that lack the necessary facilities and resources for vaccine development. Growing population, the prevalence of infectious diseases, rising demand for vaccines, expanding biopharmaceutical industry, growing urbanization and industrialization, increased demand for vaccine introduction, and rising vaccine awareness in this country are expanding the growth of the North American vaccine contract manufacturing market.

It provides a wide range of services, including production process, cell line creation, manufacturing product construction and operation, process optimization, fermentation, and analytical characterization, which are further expected to accelerate the market expansion in the future years. In addition, increasing focus on specialty medicines, combined with technological advancements such as artificial intelligence, IoT, and big data for vaccine manufacturing, as well as government initiatives and rising public health concerns, has created a huge opportunity for the North American vaccine contract manufacturing market to grow over the forecast period.

Lack of appropriate and sufficient infrastructure, a weak information management system across the region, vaccine stockout issues, insufficient human resource capacity, particularly at the periphery, and the need for constant monitoring at ideal storage temperatures are all stumbling blocks for the North American vaccine contract manufacturing market. In addition, recent price pressure, regulatory difficulties, and patent expiration are expected to influence the North American vaccine contract manufacturing market negatively.

This research report on the North America vaccine contract manufacturing market has been segmented and sub-segmented into the following categories:

By Service Type:

  • Bulk Product
  • Fill Finish

By Product Type:

  • Single Vaccine
    • Influenza Virus
    • Ebola Virus
    • Chickenpox
    • Tetanus
    • Tuberculosis
    • Polio
    • Smallpox
    • Others
  • Combination Type

By Vaccine Type:

  • Inactivated Vaccines
  • Conjugate Vaccines
  • Live Attenuated Vaccines
  • Toxoid Vaccines
  • Recombinant Vector Vaccines
  • Subunit Vaccines
  • Synthetic Vaccines

By Country:

  • The United States
  • Canada
  • Rest of North America

Because of the extensive manufacture of vaccines in this area and the rising presence of a significant number of biopharmaceutical facilities, North America is estimated to account for a considerable market share in the coming years. State and federal regulations governing the production of vaccines and other biologics in North America, particularly in the United States and Canada, are likely to substantially influence contract manufacturing organizations (CMOs) and contract research organizations (CROs) advancement in the area. Contract manufacturers in the region are benefiting from the growing trend of outsourcing. The rising incidence of infectious diseases and the rising number of fatalities from vaccine-preventable diseases have raised the need for vaccines due to the rise in infectious illnesses and the emergence of endemics and pandemics. Because of the growing focus on preventing mortality caused by vaccine-preventable illnesses, North America is expected to provide the most income to the commercial vaccine industry. The introduction of the RNA platform has accelerated the creation of vaccines. Because of the growing focus on preventing mortality caused by vaccine-preventable illnesses, North America is expected to provide the most income to the commercial vaccine industry. The introduction of the RNA platform has hastened the development of vaccines.

KEY MARKET PLAYERS:

A few promising companies in the North America vaccine contract manufacturing market profiled in this report are Thomas Jefferson University, Goodwin Biotechnology Inc., BioMARK, Emergent BioSolutions, Soligenix Inc., Catalent Biologics, Minneapolis Medical Research Foundation (MMRF), Bavarian Nordic A/S, and FUJIFILM Diosynth Biotechnologies.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample